The purpose of this study is to investigate whether psilocybin-assisted therapy is effective in treating symptoms of treatment-resistant depression in people diagnosed with bipolar II disorder.
The purpose of this study is to contribute to improving our understanding of functioning in psychosis. Memory is an important predictor of how well individuals affected by schizophrenia and related psychoses are able function in their social and occupational lives. However, the exact structures and functions in the brain responsible for this relationship are currently unknown.
The purpose of this study is to examine the efficacy of the drug Cariprazine (VRAYLAR®) in improving cognition in patients with bipolar disorder.
This is a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to assess the cognitive effects of lurasidone in bipolar I and II patients (manic depression) who are in remission from an episode. Participants who show cognitive impairment at the screening visit will be enrolled into the study and randomized at the baseline visit to receive either lurasidone or placebo adjunctive therapy in a 1:1 ratio for 6 weeks.
The purpose of this study is to assess the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive (does not enter the body) technique in improving depressive symptoms.
Patients with bipolar I disorder (BD) experience depression 3 times more frequently than mania, and antidepressants are prescribed as adjuncts to mood stabilizers in up to 70% of patients. However, no placebo-controlled trials have assessed the efficacy or safety of modern antidepressants in combination with mood stabilizers in the maintenance treatment of BD. The investigators propose a multicentre, randomized, double-blind clinical trial comparing mood stabilizer plus antidepressant (escitalopram or bupropion XL) to mood stabilizer plus placebo in the maintenance treatment of BD.